The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis
Limin Zhang,Yujia Liu,Shuai Zhao,Zhen Wang,Miaomiao Zhang,Su Zhang,Xinzhuo Wang,Shuang Zhang,Wenyan Zhang,Liying Hao,Guangyu Jiao
DOI: https://doi.org/10.2147/COPD.S359873
2022-06-10
International Journal of COPD
Abstract:Limin Zhang, 1 Yujia Liu, 2 Shuai Zhao, 1 Zhen Wang, 1 Miaomiao Zhang, 1 Su Zhang, 1 Xinzhuo Wang, 1 Shuang Zhang, 1 Wenyan Zhang, 1 Liying Hao, 3 Guangyu Jiao 1 1 Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, People's Republic of China; 2 College of Traditional Chinese Medicine, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, 110032, People's Republic of China; 3 Department of Pharmaceutical Pharmacology and Toxicology, China Medical University, Shenyang, Liaoning, 110000, People's Republic of China Correspondence: Guangyu Jiao, Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China, Tel +8618940251105, Email Purpose: Chronic obstructive pulmonary disease (COPD)-related pulmonary hypertension (PH) is one of the most common comorbidities of COPD, and often leads to a worse prognosis. Although the estimated prevalence and risk factors of COPD-related PH have been widely reported, these results have not been well integrated. This study aimed to review the worldwide incidence and prevalence of COPD-related PH and explore possible factors affecting its prevalence. Patients and Methods: We searched four electronic databases (Web of Science, Embase, Cochrane, and MEDLINE) to identify all observational studies on the prevalence of COPD-related PH from database creation until July 20, 2021. Eligibility screening, quality assessment, and data extraction of the retrieved studies were independently conducted by two reviewers. Meta-analyses were performed to determine the prevalence of PH in the COPD population. Random-effects meta-regression model analyses were conducted to investigate the sources of heterogeneity. Results: Altogether, 38 articles were included in the meta-analyses. The pooled prevalence was 39.2% (95% CI: 34.0– 44.4, I 2 = 97.6%) for COPD-related PH. Subgroup analyses showed that the prevalence of PH increased with COPD severity, where the majority (30.2%) had mild PH and the minority had severe PH (7.2%). Furthermore, we found a significant regional difference in the prevalence of COPD-related PH ( P = 0.000), which was the highest in Africa (64.0%) and the lowest in Europe (30.4%). However, stratified studies on other factors involving mean age, sex, enrolment time, participant recruitment settings, and PH diagnostic methods showed no significant differences in prevalence ( P > 0.05). Conclusion: The global incidence of PH in the COPD population is very high, and there are significant regional and international variations. Patients with COPD should be screened for PH and contributing risk factors to reduce the burden on individuals and society. Keywords: chronic obstructive pulmonary disease, pulmonary hypertension, prevalence, heterogeneity, meta-analysis Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable condition characterized by persistent respiratory symptoms and restricted airflow due to abnormalities in the airways or alveoli, usually caused by high exposure to toxic particles or gases. 1,2 COPD is the most common cause of chronic respiratory disease-attributable deaths, which has become a major global health problem because of its high prevalence (approximately 10% in the adult population) and increasing incidence every year (partly related to the aging population), resulting in extremely significant increases in associated personal, social, and economic costs. 3,4 The 2017 Global Burden of Disease (GBD) Study estimates that the global mortality of COPD is approximately 41.9 deaths per 100 000 individuals (5.7% of total all-cause deaths). Specifically, 46.7 deaths per 100 000 men, and 37.0 deaths per 100 000 women are attributable to COPD. 5 In the United States, hospital expenses for this condition result in more than 13 billion dollars every year. 6 In addition to effects on the lungs, patients with COPD exhibit many systemic effects, with mean pulmonary arterial pressure (PAP) >20 mmHg at rest in up to 90% of the patients. 7,8 Studies have shown that most patients with severe emphysema have an mPAP of 20 to 25 mmHg. 9 In contrast, COPD patients very rarely (approximately 1%) have an mPAP >40 mmHg, provided that no other condition is causing PH. 9 Pulmonary hypertension (PH), a serious and common complication in the COPD population, has a dramatic correlation with worsening clinical symptoms and progn -Abstract Truncated-
English Else